SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation and kill more cancer cells. It is not yet known whether chemoradiotherapy plus peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying chemoradiotherapy and peripheral stem cell transplantation to see how well they work compared to combination chemotherapy in treating patients with stage II, stage III, or stage IV non-Hodgkin's lymphoma.

Conditions

• Lymphoma

Interventions

BIOLOGICAL

rituximab

375 mg/m2 IV every 21 days

DRUG

CHOP regimen

DRUG

carmustine

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

prednisone

DRUG

vincristine sulfate

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Cancer and Leukemia Group B

  collaborator NETWORK

• Eastern Cooperative Oncology Group

  collaborator NETWORK

• NCIC Clinical Trials Group

  collaborator NETWORK

• SWOG Cancer Research Network

  lead NETWORK

Principal Investigators

• Patrick J. Stiff, MD · Loyola University

• Thomas C. Shea, MD · UNC Lineberger Comprehensive Cancer Center

• David P. Schenkein, MD · Tufts Medical Center Cancer Center

• Stephen Couban, MD · Cancer Care Nova Scotia

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

15 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1997-07-31

Primary Completion

2008-06-01

Completion

2013-10-31

Countries

• United States
• Canada

Study Locations